LONDON (Alliance News) - Biotechnology company PureTech Health PLC on Thursday said Vedanta Biosciences, a company which PureTech founded, has entered into a collaboration with the New York University Langone Medical Center.
PureTech holds a 75.4% stake in Vedanta Biosciences.
The partnership will be focused on developing microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.
"Recent studies have highlighted the role of the microbiome in immuno-oncology, and it's exciting to work with Dr. Weber and the NYU Langone Medical Center to expand Vedanta's pipeline of immune-boosting microbiome derived therapeutics and checkpoint inhibitor combinations," PureTech Chief Executive Daphne Zohar said in a statement.
Shares in PureTech were trading down 1.6% at 158.50 pence on Thursday.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)